Design Therapeutics (DSGN)
(Delayed Data from NSDQ)
$4.75 USD
+0.04 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $4.76 +0.01 (0.21%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Design Therapeutics, Inc. [DSGN]
Reports for Purchase
Showing records 1 - 20 ( 21 total )
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Getting The Strategic Ducks In A Row -- Await Update In Early 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Management Transition As DSGN Moves In Different Direction
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving to Neutral, $6 Target; Back To Formulation, Shifting Out Timelines
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Cylinders Firing For DSGN As Pipeline Efforts Progress [4Q22 Takeaways]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DT-216 Did What It Aimed To Do In SAD, But Protein Expression Longer-Term Goal
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DT-216 Data Tracks To December, With An Additional Mid-2023 Update to Follow
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- The Wedbush Monthly Check-Up: October 2022
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Design Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Setting Our Sights On 4Q22 For DT-216 Preliminary Data -- 2Q22 Highlights
Provider: Wedbush Securities Inc.
Analyst: CHICO L